We are live on !
Find out more
TCG Crossover Management Portfolio holdings
AUM
$4.16B
Turnover
31.15%
1-Year Est. Return
983.43%
This Fund
S&P 500
This Quarter Est. Return
+22.55%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$679M
AUM Growth
+$69.3M
(+11%)
Cap. Flow
+$84.1M
Cap. Flow % of AUM
Cap. Flow %
12.38%
Top 10 Holdings %
Top 10 Hldgs %
61.79%
Holding
30
New
8
Increased
3
Reduced
2
Closed
4
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Structure Therapeutics
GPCR
|
+$37.1M |
| 2 |
Inhibrx, Inc. Common Stock
INBX
|
+$36.6M |
| 3 |
Savara
SVRA
|
+$35.7M |
| 4 |
Compass Pathways
CMPS
|
+$34.2M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$20.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$96.3M |
| 2 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$52.9M |
| 3 |
Immunovant
IMVT
|
+$7.23M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$5.49M |
| 5 |
Alpine Immune Sciences Inc
ALPN
|
+$2.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
C4 Therapeutics
CCCC
$341M
| $2.37M | 0.35% |
1,276,574
| – | – |
2023 Q1
2 quarters
|
|
|
27
Aclaris Therapeutics
ACRS
$483M
| – | – |
-529,839
| Closed | -$5.49M | – |
|
|
28
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-253,069
| Closed | -$2.6M | – |
|
|
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-2,448,829
| Closed | -$96.3M | – |
|
|
VECT
30
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-3,113,600
| Closed | -$52.9M | – |
|
Similar funds
TCG Crossover Management's Q3 2023 Portfolio in Review
As of Q3 2023, TCG Crossover Management held 30 positions worth $679M, up 11% from $610M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
TCG Crossover Management deployed $84.1M of net new capital in Q3 2023, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Immunovant, an estimated $7.23M trimmed.
- TCG Crossover Management's largest Q3 2023 buy was Inhibrx, Inc. Common Stock: 1,750,387 shares worth $32.1M.
- TCG Crossover Management added most to Structure Therapeutics in Q3 2023, an estimated $37.1M increase.
- TCG Crossover Management's biggest Q3 2023 reduction was Immunovant, cutting an estimated $7.23M.
- TCG Crossover Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $96.3M.
- TCG Crossover Management's ten largest holdings make up 62% of its $679M portfolio in Q3 2023.
- TCG Crossover Management opened 8 new positions and closed 4 in Q3 2023.
- TCG Crossover Management's portfolio value rose 11% quarter-over-quarter to $679M.
Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.